8 completed, 2 active not recruiting, 2 terminated. 8 Phase 2, 1 Not applicable, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 5, Terminated 2, Active not recruiting 1 |
| Not applicable | 1 | Completed 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Tongue Carcinoma: new trials by email Literature Review of Tongue Carcinoma trials Research Report on Tongue Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Submental Island Flap vs Radial Forearm Free Flap in Tongue Reconstruction Submental Island Pedicled Flap (SIPF), Radial Forearm Free Flap (RFFF) - Tongue Carcinoma, Tongue Neoplasms | Completed | Al-Azhar University | 28 | 2024-09-01 | 2026-09-15 | |
| Customized 3D Printed Oral Stents During Head and Neck Radiotherapy Best Practice, Medical Device Usage and Evaluation - Head and Neck Carcinoma, Malignant Parotid Gland Neoplasm | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 88 | 2021-05-26 | 2026-10-06 |
| Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer Cisplatin, IMRT 6 weeks, IMRT 5 weeks - Stage III Oropharyngeal Squamous Cell Carcinoma, Stage IVA Oropharyngeal Squamous Cell Carcinoma | Phase 2 | Completed | NRG Oncology | 316 | 2014-10-01 | 2026-05-22 |
| Interstitial Photodynamic Therapy in Treating Patients With Recurrent Head and Neck Cancer Laboratory Biomarker Analysis, Photodynamic Therapy, Porfimer Sodium - Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma | Phase 2 | Terminated | Roswell Park Cancer Institute | 3 | 2014-04-01 | 2017-10-11 |
| Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Cisplatin, Laboratory Biomarker Analysis, Pharmacological Study - Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 6 | 2014-03-01 | 2017-05-03 |
| Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer Cetuximab, Laboratory Biomarker Analysis, Lenalidomide - Recurrent Colon Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma | Phase 1 | Completed | National Cancer Institute (NCI) | 24 | 2011-02-10 | 2020-03-13 |
| Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy Cetuximab, Laboratory Biomarker Analysis, Temsirolimus - Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 86 | 2010-11-01 | 2017-03-27 |
| Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma Laboratory Biomarker Analysis, Vorinostat - Recurrent Oral Cavity Adenoid Cystic Carcinoma, Recurrent Salivary Gland Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 30 | 2010-08-06 | 2020-08-03 |
| Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery Laboratory Biomarker Analysis, Soy Isoflavones, Survey Administration - Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 55 | 2009-07-01 | 2016-10-24 |
| Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Bevacizumab, Carboplatin, Cisplatin - Neck Squamous Cell Carcinoma of Unknown Primary, Recurrent Hypopharyngeal Squamous Cell Carcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 403 | 2008-08-08 | 2026-10-22 |
| Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer Cediranib Maleate, Laboratory Biomarker Analysis - Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 6 | 2007-02-01 | 2015-05-05 |
| Improving Therapeutic Outcomes in the Tongue Carcinoma Patient: Assessment of Adaptation Using Functional Magnetic Resonance Imaging and Diffusion Tensor Imaging MRI - Tongue Carcinoma | Not applicable | Completed | Memorial Sloan Kettering Cancer Center | 99 | 2002-11-01 | 2014-06-12 |
Tongue Neoplasms (12) · Squamous Cell Carcinoma of Head and Neck (8) · Lymphoid Interstitial Pneumonia (7) · Salivary Gland Neoplasms (5) · Carcinoma (1) · Colonic Neoplasms (1) · Maxillary Sinus Neoplasms (1) · Mouth Neoplasms (1) · Neoplasms (1) · Parotid Neoplasms (1) · Rectal Neoplasms (1) · Tonsillar Neoplasms (1)
Head and Neck Neoplasms (12) · Mouth Diseases (12) · Neoplasms by Site (12) · Stomatognathic Diseases (12) · Tongue Diseases (12) · Mouth Neoplasms (11) · Neoplasms (11) · Neoplasms by Histologic Type (9) · Neoplasms, Glandular and Epithelial (9) · Carcinoma (8) · Carcinoma, Squamous Cell (8) · Salivary Gland Diseases (6) · Colonic Diseases (1) · Colorectal Neoplasms (1) · Digestive System Diseases (1)
Cisplatin (3) · 1,2-diaminocyclohexaneplatinum II citrate (2) · Cetuximab (2) · Platinum (2) · 1-phenyl-3,3-dimethyltriazene (1) · Bevacizumab (1) · Carboplatin (1) · Dihematoporphyrin Ether (1) · Disulfides (1) · Docetaxel (1) · Fluorouracil (1) · Immunoglobulin G (1) · Lenalidomide (1) · Photochemotherapy (1) · Phototherapy (1)
National Cancer Institute (NCI) (7) · Al-Azhar University (1) · M.D. Anderson Cancer Center (1) · Memorial Sloan Kettering Cancer Center (1) · NRG Oncology (1) · Roswell Park Cancer Institute (1)
United States (10) · Canada (3) · China (1) · Egypt (1) · Ireland (1) · Puerto Rico (1) · Saudi Arabia (1) · South Africa (1)
Anna Lee (1) · Eric Winquist (1) · Erin M Bertino (1) · Greg Wolf (1) · Hassan Arshad (1) · James Rocco (1) · Kyung Peck, PhD (1) · Mohamed Serag Attia, MSc (1) · Patricia LoRusso (1) · Sue Yom (1) · Tanguy Seiwert (1)
N01CM00032 (1), N01CM00071 (1), N01CM00099 (1), N01CM62201 (1), P30CA006516 (1), P30CA014599 (1), P30CA016056 (1), P30CA016058 (1), P30CA022453 (1), P30CA046592 (1), R21CA119591 (1), U01CA062487 (1), U01CA062502 (1), U01CA062505 (1), U01CA076576 (1)